Biosensor nanoparticles deliver cancer drug with precise, 3-D imaging

Biosensors improve drug targeting with imaging capabilities.--Courtesy of the Garvan Institute

Researchers in the U.S., the U.K. and Australia have developed a biosensor nanotechnology that could improve drug delivery for the treatment of pancreatic cancer while allowing for imaging at the same time, according to a release from the Garvan Institute in Australia. The biosensors deliver Bristol-Myers Squibb's ($BMY) Phase II antitumor drug dasatinib while also showing how cancers spread and how they respond to the drug in real time via three-dimensional visualization. The nanoparticles, as shown in a study published in the journal Cancer Research, could also be used in combination therapies to break down tissue around a tumor for better drug delivery. Release | Study (PDF)

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…